Skip to content

Study · Systematic review · n = 562 · 2026

2 results

Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Kanbay M, Shah E, AlShiab R, Ozbek L, Ay S, Rustamov A, Covic A, Mallamaci F, Zoccali C

Diabetes, obesity & metabolism14 Jul 2026Cited by 2 (Europe PMC)

PMID42449480 (opens in a new tab)PMCIDPMC13538776 (opens in a new tab)DOI10.1111/dom.71106 (opens in a new tab)PepBankPUB-42449480
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, a meta-analysis of two tirzepatide RCTs showed a significant reduction in IL-6.

    In plain wordsIn adults with type 2 diabetes, two trials of tirzepatide showed lower levels of the inflammation marker IL-6.

    Peptide
    Tirzepatide
    Outcome
    DecreaseInterleukin-6 (IL-6)
    Study

    n = 562

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    SMD
    −0.28
    IL-6

    Source sentences

    Summary
    Two tirzepatide RCTs (562 participants) showed a significant reduction in IL-6 (SMD -0.28, 95% CI -0.47 to -0.09) and a non-significant trend towards lower CRP/hs-CRP.
    1 context sentence
    Summary · context
    randomised controlled trials (RCTs) in adults with T2DM comparing a GLP-1RA or dual GIP/GLP-1 agonist with placebo or active therapy
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, two tirzepatide RCTs showed a non-significant trend towards lower CRP/hs-CRP.

    In plain wordsIn adults with type 2 diabetes, two trials of tirzepatide showed a trend to lower CRP that was not statistically significant.

    Peptide
    Tirzepatide
    Outcome
    No significant changeC-reactive protein (CRP/hs-CRP)
    Study

    n = 562

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Two tirzepatide RCTs (562 participants) showed a significant reduction in IL-6 (SMD -0.28, 95% CI -0.47 to -0.09) and a non-significant trend towards lower CRP/hs-CRP.
    1 context sentence
    Summary · context
    randomised controlled trials (RCTs) in adults with T2DM comparing a GLP-1RA or dual GIP/GLP-1 agonist with placebo or active therapy

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.